China says talks to include Paxlovid in its insurance drug list fail

Paxlovid in an update to its list of medicines covered by basic medical insurance schemes as the U.S. firm quoted a high price for the COVID-19 drug, China's Healthcare Security Administration said on Sunday.

Inclusion on the list means a drug is accessible via state insurance schemes, which will boost volumes but comes with the condition that manufacturers lower prices. Past rounds have seen drugmakers cut prices by as much as 62% after negotiations with officials. While the talks on Paxlovid failed, they succeeded with two other COVID-19 treatment drugs -- herbal medication Qingfei Paidu granules and Chinese drugmaker Genuine Biotech's Azvudine -- which will be included in the list's update, the regulator said.

🇪🇺🇺🇸

意料之中！ 已经能死尽死了，没死的也短期内有抗体了，谁还能花高价引进这个药？何况通过手段自己仿制也不难，阿三哥都能做到的，中国没有理由做不到

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

China says talks to include Paxlovid in state health insurance failChina's Health Security Administration said on Sunday that talks to include Pfizer's Paxlovid in the latest drug list for basic state health insurance did not succeed. I dobrze👍 Pfizer's Paxlovid is priced much higher in China than in Europe and the US, This is unfair to us Chinese.🙃 Won't China just rip it off like they do everything else?
Source: Reuters - 🏆 2. / 97 Read more »